Join to View Full Profile
100 Medical PlazaSuite 550Los Angeles, CA 90095
Phone+1 310-794-4955
Fax+1 310-794-4955
Dr. Oliai is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Hematology and Medical Oncology, 2016 - 2019- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 2014 - 2016
California Pacific Medical CenterResidency, Radiation Oncology, 2012 - 2016
Drexel University College of Medicine/Hahnemann University HospitalInternship, Internal Medicine, 2011 - 2012- Drexel University College of MedicineClass of 2011
Certifications & Licensure
CA State Medical License 2012 - 2026
PA State Medical License 2011 - 2012
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia Start of enrollment: 2024 Aug 03
- Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma Start of enrollment: 2023 Jan 23
- Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies Start of enrollment: 2022 Jun 21
- Join now to see all
Publications & Presentations
PubMed
- CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial.Caspian Oliai, Sunmin Park, Lloyd E Damon, Brian A Jonas, Deepa Jeyakumar
Leukemia & Lymphoma. 2025-04-01 - 1 citationsAllogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies.Yan-Ruide Li, Ying Fang, Siyue Niu, Yichen Zhu, Yuning Chen
Nature Communications. 2025-02-01 - 2 citationsImpact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.Ibrahim Aldoss, Gregory W Roloff, Rawan Faramand, Noam E Kopmar, Chenyu Lin
Blood Advances. 2024-12-10
Authored Content
- Optimizing Outcomes with Myeloablative Conditioning in Older Patients: Efficacy and Safety of Precision Engineered Orca-T in Patients > 55 Years Old with Hematologic MalignanciesDecember 2023
Press Mentions
Orca Bio Presents Positive Data Demonstrating the Potential for Orca-T and Orca-Q to Expand Treatment to Additional Patient Groups at the 65th ASH Annual MeetingDecember 12th, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
